Creo Medical Group (LON:CREO) Stock Price Down 9.5% - Here's Why

Creo Medical Group PLC (LON:CREO - Get Free Report) shares were down 9.5% on Monday . The company traded as low as GBX 17 ($0.21) and last traded at GBX 17.20 ($0.22). Approximately 1,215,246 shares changed hands during trading, an increase of 67% from the average daily volume of 726,307 shares. The stock had previously closed at GBX 19 ($0.24).

Creo Medical Group Stock Performance

The firm has a market capitalization of £62.86 million, a PE ratio of -2.46 and a beta of 0.86. The company has a current ratio of 3.24, a quick ratio of 2.19 and a debt-to-equity ratio of 29.96. The business's 50 day simple moving average is GBX 18.54 and its two-hundred day simple moving average is GBX 21.40.

Insider Buying and Selling at Creo Medical Group

In other Creo Medical Group news, insider Richard John Rees acquired 4,712 shares of the business's stock in a transaction dated Thursday, January 16th. The stock was purchased at an average price of GBX 19 ($0.24) per share, with a total value of £895.28 ($1,131.12). Also, insider Kevin Crofton acquired 1,179,000 shares of the business's stock in a transaction dated Friday, December 13th. The shares were acquired at an average cost of GBX 17 ($0.21) per share, with a total value of £200,430 ($253,228.05). In the last ninety days, insiders purchased 1,188,424 shares of company stock worth $20,222,056. Insiders own 22.43% of the company's stock.

Creo Medical Group Company Profile

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy. The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive.